The ROC curve analysis indicated that serum cTnT had a sensitivity of 51.1% and a specificity of 88.4%, respectively, in evaluating pre-clinical cardiovascular injury in NSCLC patients (cutoff point, 0.0105 ng/mL; AUC value, 0.720; see Figure 3B). This evidence concerns the gene TNNT2 and non-small cell lung carcinoma.